Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Beach

Showing results (281-290 of 320) with videos related to

Pageof 32
Sort By:
International Journal of Radiation Oncology, Biology, Physics|December 1, 1980
A clinical trial for advanced cervico-vaginal pelvic carcinomas using Californium Cf-252 fast neutron therapy: report of early responsesY Maruyama, J Yoneda, H Krolikiewicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromesRoger M Lyons, Thomas M Cosgriff, Sanjiv S Modi, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|January 18, 2014
Microbubbles are detected prior to larger bubbles following decompressionJ G Swan, J C Wilbur, K L Moodie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2011
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failureThomas Prébet, Steven D Gore, Benjamin Esterni, et al.
Haematologica|November 4, 2017
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemiaBruno C Medeiros, Kelly McCaul, Suman Kambhampati, et al.
Asia-Pacific Journal of Clinical Oncology|December 29, 2017
Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 studyXin Du, Yue-Yun Lai, Zhijian Xiao, et al.
Haematologica|March 23, 2023
Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trialAndrew H Wei, Gail J Roboz, Herve Dombret, et al.
British Journal of Haematology|February 9, 2010
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-CPierre Fenaux, Norbert Gattermann, John F Seymour, et al.
Clinical Pharmacokinetics|July 24, 2019
Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic MalignanciesKen Ogasawara, Kathryn Newhall, Stephen E Maxwell, et al.
Anesthesia and Analgesia|March 20, 2015
Transmission dynamics of gram-negative bacterial pathogens in the anesthesia work areaRandy W Loftus, Jeremiah R Brown, Hetal M Patel, et al.
Pageof 32

Showing results (281-290 of 320) with videos related to

Sort By:
Pageof 32
International Journal of Radiation Oncology, Biology, Physics|December 1, 1980
A clinical trial for advanced cervico-vaginal pelvic carcinomas using Californium Cf-252 fast neutron therapy: report of early responsesY Maruyama, J Yoneda, H Krolikiewicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromesRoger M Lyons, Thomas M Cosgriff, Sanjiv S Modi, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|January 18, 2014
Microbubbles are detected prior to larger bubbles following decompressionJ G Swan, J C Wilbur, K L Moodie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2011
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failureThomas Prébet, Steven D Gore, Benjamin Esterni, et al.
Haematologica|November 4, 2017
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemiaBruno C Medeiros, Kelly McCaul, Suman Kambhampati, et al.
Asia-Pacific Journal of Clinical Oncology|December 29, 2017
Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 studyXin Du, Yue-Yun Lai, Zhijian Xiao, et al.
Haematologica|March 23, 2023
Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trialAndrew H Wei, Gail J Roboz, Herve Dombret, et al.
British Journal of Haematology|February 9, 2010
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-CPierre Fenaux, Norbert Gattermann, John F Seymour, et al.
Clinical Pharmacokinetics|July 24, 2019
Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic MalignanciesKen Ogasawara, Kathryn Newhall, Stephen E Maxwell, et al.
Anesthesia and Analgesia|March 20, 2015
Transmission dynamics of gram-negative bacterial pathogens in the anesthesia work areaRandy W Loftus, Jeremiah R Brown, Hetal M Patel, et al.
Pageof 32